ClinicalTrials.gg
CompletedNCT07655427Updated Jun 17, 2026

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects

A Phase 1 interventional study of SRSD107 and Placebo in Thrombus, sponsored by Sirius Therapeutics Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Sirius Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Mar 2024, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Thrombosis with a site in China — 18 open to participants now, 20 under way, none of them phase 3. Thrombosis · China.

Enrollment
34th of 41
48 · median 274
Started
2024
with 2 others
Phase 1
8 of 67
none open now
Registered
65th of 67
by date

Among the 67 studies in Thrombosis with a site in China, this one is the 34th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 in phase 1, and was the 65th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

18 of the 67 studies in Thrombosis with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Thrombosis with a site in China, or all of them as a file.
02

Study summary

This was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered SRSD107 in Chinese healthy subjects. SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.

03

Conditions studied

  • Thrombus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, of any race, between 18 and 65 years of age, inclusive.
  • between 18.0 and 32.0 kg/square meter, inclusive.
  • In good health, determined by no findings from medical history, physical examination, clinical laboratory evaluations, 12 lead , and vital signs measurements, at screening and check in, as assessed by the investigator (or designee).
  • and prothrombin time within the normal reference range.
  • Females will not be pregnant or lactating, and females of and males will agree to use as pre-defined in the protocol.
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • History or evidence of any abnormal bleeding or coagulation disorder; or evidence of coagulopathy, prolonged or unexplained, bleeding, or frequent unexplained bruising or thrombus formation; or a history of spontaneous bleeding.
  • Evidence of an active or suspected cancer, or a history of , within 5 years prior to screening. Nonmelanoma skin cancer, curatively treated localized prostate cancer, or other carcinoma in situ are not exclusionary, providing that they did not require systemic therapy and are considered cured.
  • Acute of febrile illness within 7 days prior to dose administration or evidence of active infection.
  • Any major surgery within 3 months prior to screening or plan to have any surgery during the study.
  • History of clinically significant , intolerance, or allergy to any drug compound, oligonucleotide, GalNAc, food, or other substance, as determined by the investigator (or designee).
  • Systolic blood pressure >140 mmHg or \<90 mmHg, or diastolic blood pressure >90 mmHg or \<50 mmHg confirmed by repeat measurement.
  • corrected for heart rate using Fridericia's method (QTcF) >450 ms confirmed by repeat measurement.
  • count or level below the lower limit of normal.
  • , aspartate aminotransferase, gamma glutamyl transferase, alkaline phosphatase, or total >1.5 × the .
  • Estimated \<80 mL/min/1.73 square meter, as calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration equation.
  • Positive and C, positive test or positive syphilis test. Subjects whose results are compatible with prior immunization may be included.
  • Positive pregnancy test at screening or check in.
  • Women who are menstruating at dosing, and women whose past volume of menstrual fluid was >80 mL or menstrual periods were >7 days.
  • Use or intend to use any of the following, as determined by the investigator (or designee): 1) prescription medications/products or herbal products within 14 days or 5 terminal elimination half lives, whichever is longer, prior to dose administration in this study; 2) over the counter medications/products within 7 days prior to dose administration in this study. Recommended doses of vitamin and mineral supplements, over the counter analgesics (eg, paracetamol or ibuprofen for the treatment of acute conditions [eg, headache]), prescription oral, implantable, transdermal, injectable, or intrauterine , and other products that have been approved by the investigator will not be exclusionary. Hormone replacement therapy will not be exclusionary, providing that the regimen has been stable for at least 2 months prior to screening and will not be changed during the study.
  • Immunization with any within 6 weeks prior to screening, or expected to require immunization with any live vaccine during the study.
  • Receipt of an drug in the past 90 days or 5 half lives of that drug, whichever is longer, prior to dosing in this study.
  • Receipt of any siRNA treatment within 12 months or any antisense oligonucleotide treatment within 6 months prior to dosing in this study.
  • Have previously completed or withdrawn from this study or any other study investigating SRSD107 and have previously received SRSD107.
  • Drug abuse or addiction within 1 year prior to screening, as determined by the investigator (or designee).
  • Positive alcohol or cotinine test result or positive urine drug screen (confirmed by repeat) at screening or check in.
  • Regular alcohol consumption of >21 units per week for males and >14 units for females within 12 months prior to screening. One unit of alcohol equals 375 mL of beer or lager (3.5%), 100 mL of wine (13.5%), or 30 mL of spirits (40%).
  • Use of tobacco or nicotine containing products within 1 months prior to screening.
  • Receipt of blood products within 3 months prior to check in.
  • Loss of >500 mL whole blood or donation of >200 mL blood products within 1 month prior to screening.
  • History of intolerance to subcutaneous injections, or scarring (eg, from surgical procedures or burns) in areas when subcutaneous dose administration may occur.
  • Poor peripheral venous access.
  • Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    SRSD107

    Drug: SRSD107

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.

  • DrugPlacebo

    Sodium chloride for subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Proportion of adverse events (AEs)

    Time frame: up to 168 days post last dose

  2. Proportion of Serious Adverse Events (SAEs)

    Time frame: up to 168 days post last dose

Secondary outcomes

  1. Peak Concentration

    Time frame: Day 1 to Day 3

  2. Time to maximum concentration

    Time frame: Day1 to Day3

  3. Elimination half-life

    Time frame: Day1 to Day3

  4. Area Under Curve

    Time frame: Day1 to Day3

  5. Apparent total clearance

    Time frame: Day1 to Day3

  6. Prothrombin Time

    Time frame: up to 168 days post last dose

  7. Activated Partial Thromboplastin Time

    Time frame: up to 168 days post last dose

  8. FXI avtivity in peripheral blood (quantitative laboratory measurement)

    Coagulation Factor XI (FXI) is a plasma serine protease zymogen predominantly synthesized in the liver. As a key protein in the intrinsic coagulation pathway, it circulates in the bloodstream as a homodimer.

    Time frame: up to 168 days post last dose

  9. FXI antigen concentration in peripheral blood (quantitative laboratory measurement)

    Coagulation Factor XI (FXI) is a plasma serine protease zymogen predominantly synthesized in the liver. As a key protein in the intrinsic coagulation pathway, it circulates in the bloodstream as a homodimer.

    Time frame: up to 168 days post last dose

07

Study locations

1 site
  • Beijing Tiantan Hospital Affiliated to Capital Medical University
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Mar 2025, 11 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 17, 2026
StartActual
Mar 29, 2024
Primary completionActual
Mar 2, 2025
CompletionActual
Mar 2, 2025
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655427
Lead sponsor
Sirius Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Mar 29, 2024
Primary completion
Mar 2, 2025
Completion
Mar 2, 2025
Last update
Jun 17, 2026

Study contacts

Qiuyue Qu
study director · Sirius Therapeutics Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRSD107

Start the discussion